Liver cirrhosis
Conditions
Interventions
None listed
Sponsors
Hokkaido University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients with liver cirrhosis who have accumulated fluid such as ascites, pleural effusion, or edema, and who have been administered diuretics or have been administered. 2 Regarding the study subjects who will newly collect samples, patients who received a sufficient explanation before participating in this study, and with sufficient understanding, obtained the written consent of the study subjects themselves. 3 Regarding research subjects whose specimens have already been stored for the purpose of research, those who have obtained free consent to participate in this research or who do not refuse to participate in the research
Exclusion criteria
Exclusion criteria: 1 Those who have a history of hypersensitivity to the components of diuretics 2 People who have difficulty taking the drug 3 Those who cannot drink water 4 Unurinated person 5 Pregnant women or women who may be pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pre-treatment AKI marker (urinary L-FABP, urine NGAL) values and changes in renal dysfunction up to 12 months after starting diuretics (eGFR, creatinine, cystatin C) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Prognosis after starting diuretics 2 Changes in AKI markers and renal function by diuretics type (eGFR, creatinine, cystatin C) 3 Prognosis according to the type of diuretics 4 Changes in diuretic dose and renal function (eGFR, creatinine, cystatin C) 5 Relationship between inflammatory response (CRP) levels and prognosis 6 Relationship between soluble CD14 value and prognosis 7 recurrence rate of fluid retention after diuretics administration 8 Relationship between water retention recurrence after diuretic administration and various blood chemistry and urine tests | — |
Countries
Japan
Contacts
Public ContactMasato Nakai
Hokkaido University Hospital Gastroenterology and Hepatology
Outcome results
None listed